The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience

Sampietro, Tiziana; Sbrana, Francesco; Bigazzi, Federico; Ripoli, Andrea; Pino, Beatrice Dal; Pasanisi, Emilio; Petersen, C.; Coceani, Michele; Luciani, R.; Pianelli, Mascia

doi:10.1016/j.atherosclerosissup.2015.02.040

Cited by 8 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive impact of LDL apheresis on cardiovascular morbidity in individuals with hypercholesterolemia has been previously confirmed in several observational trials [38]. Sampietro et al [39] reported a significant reduction of adverse cardiac or vascular events in 30 individuals with FH or familial combined hypercholesterolemia and CVD. Adverse cardiac or vascular events incidences occurred prior and after LA treatment inception, which were 86 and 15 events, respectively [39].…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre

et al. 2020

View full text Add to dashboard Cite

Background: Severe familial hypercholesterolemia (FH) individuals, refractory to conventional lipidlowering medications are at exceptionally high risk of cardiovascular events. The established therapeutic option of last choice is lipoprotein apheresis (LA). Herein, it was sought to investigate the clinical usefulness of LA in a highly selected group of severe heterozygous FH (HeFH), as recently described by the International Atherosclerosis Society (IAS), for their efficacy in lipid reduction and safety. Methods: Efficacy and safety of LA were investigated in 318 sessions of 7 severe HeFH females with cardiovascular disease, over a mean period of 26.9 ± 6.5 months. Relative reduction of low density lipoprotein cholesterol (LDL-C) ≥ 60%, clinical complications and vascular access problems were evaluated and compared between the direct adsorption of lipoproteins (DALI) and lipoprotein filtration (Membrane Filtration Optimized Novel Extracorporeal Treatment [MONET]). Additionally, lipoprotein (a) [Lp(a)], total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and fibrinogen concentrations were investigated.

show abstract

Section: Discussionmentioning

confidence: 79%

“…Sampietro et al [39] reported a significant reduction of adverse cardiac or vascular events in 30 individuals with FH or familial combined hypercholesterolemia and CVD. Adverse cardiac or vascular events incidences occurred prior and after LA treatment inception, which were 86 and 15 events, respectively [39].…”

Section: Discussionmentioning

confidence: 99%

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In general, lipoprotein apheresis is recommended for patients with homozygous FH and heterozygous FH with CVD refractory to lipid‐lowering drug therapy or statin‐intolerant FH patients . Weekly or bi‐weekly lipoprotein apheresis selectively removes apoB‐containing lipoproteins (sparing HDL‐C) and can achieve LDL‐C and Lp(a) reductions of 50%‐75% …”

Section: Promising Therapiesmentioning

confidence: 99%

“…In cases of high Lp(a) inadequately controlled with available therapeutic options and high CVD risk, Lp(a) apheresis is a quite effective method, which seems also to reduce CVD events. 106,107 In general, lipoprotein apheresis is recommended for patients with homozygous FH and heterozygous FH with CVD refractory to lipid-lowering drug therapy or statin-intolerant FH patients. 108 Weekly or bi-weekly lipoprotein apheresis selectively removes apoB-containing lipoproteins (sparing HDL-C) and can achieve LDL-C and Lp(a) reductions of 50%-75%.…”

Section: Lp(a) Apheresismentioning

confidence: 99%

See 1 more Smart Citation

Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options

et al. 2016

View full text Add to dashboard Cite

show abstract

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

Schwartz

Padmanabhan

Aqui

et al. 2016

J of Clinical Apheresis

581

1,181

View full text Add to dashboard Cite

The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the Committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Seventh Edition of the JCA Special Issue continues to maintain this methodology and rigor to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Seventh Edition, like its predecessor, has consistently applied the category and grading system definitions in the fact sheets. The general layout and concept of a fact sheet that was used since the fourth edition has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. The Seventh Edition discusses 87 fact sheets (14 new fact sheets since the Sixth Edition) for therapeutic apheresis diseases and medical conditions, with 179 indications, which are separately graded and categorized within the listed fact sheets. Several diseases that are Category IV which have been described in detail in previous editions and do not have significant new evidence since the last publication are summarized in a separate table. The Seventh Edition of the JCA Special Issue serves as a key resource that guides the utilization of therapeutic apheresis in the treatment of human disease. J. Clin. Apheresis 31:149-162, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience

Cited by 8 publications

References 20 publications

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre

Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre

Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue

Contact Info

Product

Resources

About